1 the mitochondrial permeability transition by
nicorandil.
2 libenclamide plus nicorandil, 100 micromol/L
nicorandil,
1 mmol/L nicorandil, and 20 mmol/L KCl was 4
3 Nicorandil (
100 microM) suppressed all of these markers
4 Nicorandil (
100 micromol/L and 1 mmol/L) significantly i
5 micromol/L, or 1 mmol/L), 20 mmol/L KCl, or
nicorandil (
100 micromol/L) plus glibenclamide (10 micro
6 Nicorandil (
100 micromol/l) significantly suppressed the
7 leit solution either alone (control) or with
nicorandil (
100 micromol/L, 300 micromol/L, or 1 mmol/L)
8 Nicorandil (
100 micromol/liter) increased flavoprotein o
9 (mean+/-SEM) for control, glibenclamide plus
nicorandil,
100 micromol/L nicorandil, 1 mmol/L nicorand
10 Nicorandil (
2 to 20 micromol/L) abbreviated the QT inter
11 Nicorandil 20 micromol/L reversed only 50% of the effect
12 Group 1 rats (n = 21) were treated with
nicorandil (
3 mg/kg/day in drinking water) for 4 days be
13 Nicorandil,
a clinically useful drug for the treatment o
14 We examined whether
nicorandil,
a clinically useful drug for the treatment o
15 This study examines the effects of
nicorandil,
a K(+) channel opener, on transmural dispers
16 Nicorandil also decreased IOP (18.9 +/- 1.8%) with an ab
17 orandil, 100 micromol/L nicorandil, 1 mmol/L
nicorandil,
and 20 mmol/L KCl was 44.1+/-3.4%, 44.9+/-2.
18 Ranolazine, trimetazidine,
nicorandil,
and ivabradine are medications that have bee
19 icantly increased in control, 300 micromol/L
nicorandil,
and nicorandil plus glibenclamide groups.
20 d with the K(ATP) channel openers diazoxide,
nicorandil,
and P1075 or the K(ATP) channel closer glybu
21 K(ATP) channel openers diazoxide and
nicorandil are effective regulators of IOP in mouse eyes
22 Our findings identify
nicorandil as an inhibitor of apoptosis induced by oxida
23 Nicorandil blunted the rate of cell death in a pelleting
24 Nicorandil can mimic ischemic preconditioning, while mit
25 yndrome and response in five patients taking
nicorandil,
ciclosporin, or isoflurane, which suggests t
26 Pooled dose-response data confirm that
nicorandil concentrations as low as 10 micromol/liter tu
27 Nicorandil exerts a direct cardioprotective effect on he
28 Pretreatment with
nicorandil for 6 days before imaging did not reduce LV d
29 ecific anal ulceration, all of whom received
nicorandil for symptomatic control of ischaemic heart di
30 The increase in LV mass was reduced in the
nicorandil group (0.73 g +/- 0.03) compared with that in
31 le in the control group and 41% +/- 2 in the
nicorandil group (difference not significant, unpaired S
32 ular obstruction regions were smaller in the
nicorandil group (eg, 3% +/- 1) than in the control grou
33 Improvement in LV function in the
nicorandil group is likely related to alleviation and re
34 also smaller (eg, 20% +/- 2) in rats in the
nicorandil group than in those in the control group (37%
35 ts on LV ejection fraction (37% +/- 3 in the
nicorandil group vs 24% +/- 3 in the control group), end
36 and 8 weeks after infarction (hereafter, the
nicorandil group).
37 the control group and 27% of animals in the
nicorandil group.
38 scular obstruction in animals in control and
nicorandil groups.
39 5 > pinacidil > levcromakalim = BMS-180448 >
nicorandil &
gt; diazoxide = BRL 38226.
40 The present results showed that
nicorandil has anti-apoptotic effects in neurons, at lea
41 Moreover,
nicorandil has been approved for human use and has not b
42 Nicorandil has been reported to have a cardioprotective
43 At functional MR imaging,
nicorandil improved systolic reduction in LV cavity area
44 Nicorandil is a vasodilator used to control angina.
45 eliminated by glibenclamide, indicating that
nicorandil is cardioprotective primarily through its cap
46 The chemical structure of
nicorandil is distinct from other PCOs, in part because
47 hypothesized that the protective effects of
nicorandil may be at least partially due to an antiapopt
48 Based on these facts, we hypothesized that
nicorandil may have anti-apoptotic effects in neurons me
49 Our results suggest that
nicorandil might be a cause of anal ulceration.
50 (ATP) channel openers diazoxide (n = 10) and
nicorandil (
n = 10) for 14 days.
51 Nicorandil (
n = 9) was infused during occlusion and earl
52 We investigated the effect of
nicorandil on apoptosis induced by oxidative stress usin
53 d in control, 300 micromol/L nicorandil, and
nicorandil plus glibenclamide groups.
54 Notably,
nicorandil prevented Delta(Psi)(m) depolarization in a c
55 membrane potential (DeltaPsim) revealed that
nicorandil prevented the loss of DeltaPsim induced by H2
56 In contrast to other PCOs,
nicorandil produced mechanical arrest as quickly as KCl
57 Nicorandil produced significant salutary effects on LV e
58 entical infarction size in 11 control and 11
nicorandil rats.
59 Recently, several studies showed that
nicorandil reduced brain injury in animal models of brai
60 Intravenous therapy with
nicorandil reduces formation of microvascular obstructio
61 individual cells loaded with TMRE shows that
nicorandil suppresses Delta(Psi)(m) loss.
62 d the recovery of LV function 24 hours after
nicorandil therapy.
63 abnormalities were observed in diazoxide- or
nicorandil-
treated eyes.
64 The protective effect of
nicorandil was eliminated by glibenclamide, indicating t
65 his study, the effectiveness of another PCO,
nicorandil,
was investigated for several reasons.
66 These protective effects of
nicorandil were blocked by the mitoK(ATP) channel antago
67 Effects of
nicorandil were evaluated using a number of apoptotic ma